<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771104</url>
  </required_header>
  <id_info>
    <org_study_id>H15000210</org_study_id>
    <nct_id>NCT04771104</nct_id>
  </id_info>
  <brief_title>The Effect of Induced Hyperammonaemia on Sleep and Melanopsin-mediated Pupillary Light Response in Patients With Liver Cirrhosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sleep disturbances are common among patients with liver cirrhosis, but the reasons are not&#xD;
      well understood. In this project the investigators evaluated whether an increase in blood&#xD;
      ammonia in patients with cirrhosis had an impact on sleep quality and the function of retinal&#xD;
      ganglion cells measured by pupillary response to blue light.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Actual">January 22, 2018</completion_date>
  <primary_completion_date type="Actual">January 9, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the late post-illumination pupillary response after intervention compared to placebo</measure>
    <time_frame>12 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <condition>Liver Cirrhosis</condition>
  <condition>Sleep Disturbance</condition>
  <arm_group>
    <arm_group_label>Allocated to intervention at first experimental day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Allocated to intervention at second experimental day</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Amino Acid Challenge (AAC)</intervention_name>
    <description>The AAC contains 54 g banana flavoured amino acid mixture added 200-300 mL of water. The AAC simulates the composition of haemoglobin in approximately 400 mL of blood.</description>
    <arm_group_label>Allocated to intervention at first experimental day</arm_group_label>
    <arm_group_label>Allocated to intervention at second experimental day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a clinical diagnosis of Child Pugh Class A or B cirrhosis&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  &gt;20 and &lt;80 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Misuse of alcohol in the preceding 6 months,&#xD;
&#xD;
          -  Episodes of hepatic decompensation leading to in-patient admissions during the&#xD;
             previous month&#xD;
&#xD;
          -  History or clinical signs of overt HE or severe sleep-wake disturbances&#xD;
&#xD;
          -  On anti-HE treatment (lactulose, rifaximin, Hepa-Merz, Generaid, Bramino)&#xD;
&#xD;
          -  History of significant head injury&#xD;
&#xD;
          -  Neurological/psychiatric comorbidity needing medical treatment&#xD;
&#xD;
          -  Taking neuroactive medication/medication known to affect sleep&#xD;
&#xD;
          -  Travel across more than two time zones in the preceding 3 months&#xD;
&#xD;
          -  Shift work in the preceding 5 years&#xD;
&#xD;
          -  Contraindications for arterial puncture (negative collateral circulation test, wrist&#xD;
             infection or vascular abnormalities).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of gastroenterology and hepatology, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>March 14, 2021</last_update_submitted>
  <last_update_submitted_qc>March 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Peter Nissen Bjerring</investigator_full_name>
    <investigator_title>Consultant hepatologist, associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

